Dallas, TX -- (SBWIRE) -- 01/16/2015 -- The report "Septicaemia – Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Septicaemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Septicaemia and special features on late-stage and discontinued projects.

Complete Report available @ http://www.rnrmarketresearch.com/septicaemia-pipeline-review-h2-2014-market-report.html

Septicaemia is caused when certain bacteria get into the bloodstream. Without prompt medical treatment, septicaemia can be fatal. People with pre-existing medical conditions are most likely to get septicaemia. Treatment options include antibiotics to kill the infection. Other terms for septicaemia include bacteraemia and blood poisoning. Septicaemia sometimes has no symptoms. When there are symptoms, they can include: Sudden high fever with chills, Generally feeling unwell, Gastrointestinal symptoms including nausea, vomiting and diarrhea, Abdominal pain, Confusion and anxiety, Shortness of breath & Rapid heart rate (tachycardia).

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Order a purchase copy of this report
http://www.rnrmarketresearch.com/contacts/purchase?rname=256215

(This is a premium report priced at US$2000 for a single user License.)

Companies discussed in this research include Cubist Pharmaceuticals, Inc., Diomune S.L, Humabs BioMed SA, Sinovac Biotech Ltd.

Scope:

- The report provides a snapshot of the global therapeutic landscape of Septicaemia

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Septicaemia and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Septicaemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Septicaemia pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Inquire before buying
http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=256215

(This is a premium report priced at US$2000 for a single user License.)

Reasons to buy:

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Septicaemia

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Septicaemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse more reports on Infectious Diseases Therapeutics
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics

Connect US:
Twitter: https://twitter.com/RnRMR
Facebook: http://www.facebook.com/pages/RnR-Market-Research/413488545356345
Google Plus: https://plus.google.com/u/0/104156468549256253075/posts